SLC2A1 and lymphoma: In the current work, we have examined a Glu–MTX conjugate targeting GLUT1 in hematologic malignancies, namely, acute lymphoblastic leukemia and non-Hodgkin’s lymphoma, and compared its effect with methotrexate, a chemotherapeutic agent widely applied in the treatment of leukemia and lymphoma.